Following its success against COVID-19, BioNTech is now focused on its cancer vaccines.
By Ameya Paleja
Buoyed by the success of its mRNA technology against COVID-19, BioNTech is now focused on its cancer vaccines. The company recently began dosing patients for its Phase II trial for an advanced melanoma vaccine in the European Union.
BioNTech calls itself a “next-generation immunotherapy company pioneering in therapies for cancer and other serious diseases.” The COVID-19 vaccine was a minor detour for the company. The company’s product pipeline is filled with mRNA vaccines targeting different types of cancers, most of which are in preclinical stages. BioNTech recently began the Phase II trial of BNT111, which will test its mRNA vaccine in combination with an antibody-drug, Libtayo, in patients with anti-PD1-relapsed Stage III/ IV melanoma. Libtayo is the commercial name for cemiplimab, co-developed by Regeneron and Sanofi, and is an anti-PD-1 monoclonal antibody.
Continue reading… “BioNTech Now Aims Its mRNA Technology at Cancer”